Log In
BCIQ
Print this Print this
 

Sublingual TNX-102, TNX-102 SL

  Manage Alerts
Collapse Summary General Information
Company Tonix Pharmaceuticals Holding Corp.
DescriptionSublingual formulation of cyclobenzaprine, a muscle relaxant
Molecular Target 5-hydroxytryptamine receptor 2A (HTR2A)
Mechanism of Action5-hydroxytryptamine receptor 2A (HTR2A) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPost-traumatic stress disorder
Indication DetailsTreat post-traumatic stress disorder (PTSD)
Regulatory Designation U.S. - Breakthrough Therapy (Treat post-traumatic stress disorder (PTSD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today